Disease · MONDO_0019369
complex regional pain syndrome
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. complex regional pain syndrome. Diseases, record MONDO_0019369. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0019369
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Highest stage of its drugs
- Phase 3, for 4 of its 28 drugs, from ClinicalTrials.gov and TTD
- Open Targets
Drugs28
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| NERIDRONIC ACID | CHEMBL55214 | Small molecule | Phase 3 | ClinicalTrials.gov and TTD | 5 | 4 | 4 | Drugs and targets |
| FENTANYL | CHEMBL596 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| HUMAN IMMUNOGLOBULIN G | CHEMBL1201599 | Phase 3 | ClinicalTrials.gov | 1 | 1 | 0 | Drugs and targets | |
| NITROUS OXIDE | CHEMBL1234579 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| KETAMINE | CHEMBL742 | Small molecule | Phase 2/3 | ClinicalTrials.gov | 4 | 4 | 4 | Drugs and targets |
| LIDOCAINE | CHEMBL79 | Small molecule | Phase 2/3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| BUPIVACAINE | CHEMBL1098 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| ETHOSUXIMIDE | CHEMBL696 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| KETAMINE HYDROCHLORIDE | CHEMBL1714 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| LENALIDOMIDE | CHEMBL848 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
1 to 10 of 28
See all 28 drugsTargets73
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| OPRM1 | Mu-type opioid receptor | 4 | Mu opioid receptor agonist; Opioid receptors; mu/kappa/delta antagonist | Phase 3 | https://conductscience.org/library/genes/4988 | Drugs and targets |
| SNAP25 | Synaptosomal-associated protein 25 | 4 | Synaptosomal nerve-associated protein 25 (SNAP-25) hydrolytic enzyme; Synaptosomal nerve-associated protein 25 (SNAP-25) inhibitor | Early phase 1 | https://conductscience.org/library/genes/6616 | Drugs and targets |
| CACNA1G | Voltage-gated T-type calcium channel | 3 | Voltage-gated T-type calcium channel blocker; Voltage-gated calcium channel modulator | Phase 2 | https://conductscience.org/library/genes/8913 | Drugs and targets |
| CACNA1H | Voltage-gated T-type calcium channel | 3 | Voltage-gated T-type calcium channel blocker; Voltage-gated calcium channel modulator | Phase 2 | https://conductscience.org/library/genes/8912 | Drugs and targets |
| CACNA1I | Voltage-gated T-type calcium channel | 3 | Voltage-gated T-type calcium channel blocker; Voltage-gated calcium channel modulator | Phase 2 | https://conductscience.org/library/genes/8911 | Drugs and targets |
| GRIN1 | Glutamate [NMDA] receptor | 3 | Glutamate [NMDA] receptor negative allosteric modulator | Phase 2/3 | https://conductscience.org/library/genes/2902 | Drugs and targets |
| GRIN2A | Glutamate [NMDA] receptor | 3 | Glutamate [NMDA] receptor negative allosteric modulator | Phase 2/3 | https://conductscience.org/library/genes/2903 | Drugs and targets |
| GRIN2B | Glutamate [NMDA] receptor | 3 | Glutamate [NMDA] receptor negative allosteric modulator | Phase 2/3 | https://conductscience.org/library/genes/2904 | Drugs and targets |
| GRIN2C | Glutamate [NMDA] receptor | 3 | Glutamate [NMDA] receptor negative allosteric modulator | Phase 2/3 | https://conductscience.org/library/genes/2905 | Drugs and targets |
| GRIN2D | Glutamate [NMDA] receptor | 3 | Glutamate [NMDA] receptor negative allosteric modulator | Phase 2/3 | https://conductscience.org/library/genes/2906 | Drugs and targets |
1 to 10 of 73
See all 73 targetsTrials29
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 2 more are not shown, since the checks do not confirm them.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02972359 | Safety of Intravenous Neridronic Acid in CRPS | Phase 3 | 580 | 2019-11-04 | Complex Regional Pain Syndrome | NERIDRONIC ACID | Its record names the disease | ClinicalTrials.gov |
| NCT03560986 | Efficacy and Safety of Intravenous Neridronic Acid in Complex Regional Pain Syndrome (CRPS) | Phase 3 | 267 | 2020-08-05 | Complex Regional Pain Syndrome (CRPS) | NERIDRONIC ACID | Its record names the disease | ClinicalTrials.gov |
| NCT01008553 | A Confirmatory Study of Fentanyl in Participants With Post-herpetic Neuralgia, Complex Regional Pain Syndrome or Postoperative Pain Syndrome | Phase 3 | 258 | 2013-07-25 | Postherpetic Neuralgia, Complex Regional Pain Syndromes (CRPS), Postoperative Pain | FENTANYL | Its record names the disease | ClinicalTrials.gov |
| NCT03530345 | Efficacy and Safety of Intravenous Neridronic Acid in CRPS | Phase 3 | 182 | 2020-08-06 | Complex Regional Pain Syndrome (CRPS) | NERIDRONIC ACID | Its record names the disease | ClinicalTrials.gov |
| NCT03879538 | Nitrous Oxide for the Treatment of Complex Regional Pain Syndrome | Phase 3 | 44 | 2024-02-09 | Complex Regional Pain Syndrome | NITROUS OXIDE | Its record names the disease | ClinicalTrials.gov |
| NCT03990649 | Study of TAK-935 as an Adjunctive Therapy in Adult Participants With Complex Regional Pain Syndrome (CRPS) | Phase 2 | 24 | 2021-07-15 | Complex Regional Pain Syndrome | SOTICLESTAT | Its record names the disease | ClinicalTrials.gov |
| NCT00822926 | Subcutaneous Botulinum Toxin for Cutaneous Allodynia - Enriched Responder Trial | Not applicable | 5 | 2017-08-15 | Pain | BOTULINUM TOXIN TYPE A | Its record names the disease | ClinicalTrials.gov |
| NCT01623271 | Treatment of Complex Regional Pain Syndrome With Once Daily Gastric-Retentive Gabapentin (Gralise) | Not applicable | 5 | 2017-04-04 | Complex Regional Pain Syndrome I (CRPS I) | GABAPENTIN | Its record names the disease | ClinicalTrials.gov |
| NCT02094352 | Randomized Controlled Trial of Ketamine Infusion With Continuous Epidural Infusion for Treatment of Complex Regional Pain Syndrome | Phase 2 | 3 | 2017-06-14 | Complex Regional Pain Syndrome | KETAMINE | Its record names the disease | ClinicalTrials.gov |
| NCT02402530 | Efficacy and Safety of Intravenous Neridronic Acid in CRPS-I | Phase 2/3 | 459 | Complex Regional Pain Syndrome, Type I | NERIDRONIC ACID | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 29
See all 29 trialsComparisons in its trials5
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| The Nitrous Oxide Group vs The Control Group: deaths from any cause | 0 of 20 | 0 of 24 | 44 | NCT03879538 | Trial comparisons |
| The Nitrous Oxide Group vs The Control Group: serious adverse events | 0 of 20 | 0 of 24 | 44 | NCT03879538 | Trial comparisons |
| Placebo Then Botox vs Botox Then Placebo: deaths from any cause | 0 of 2 | 0 of 3 | 5 | NCT00822926 | Trial comparisons |
| Placebo Then Botox vs Botox Then Placebo: serious adverse events | 0 of 2 | 0 of 3 | 5 | NCT00822926 | Trial comparisons |
| Ketamine Infusion + Epidural Infusion + Booster Infusion vs Control Group + Epidural Infusion + Booster Infusion: serious adverse events | 0 of 2 | 0 of 1 | 3 | NCT02094352 | Trial comparisons |
Papers from its trials9
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0019369
GET https://conductscience.org/api/diseases/v1/MONDO_0019369/drugs?page=2